Omeprazole (A2845): Actionable Guidance for Gastric Acid Secretion Research

What This Product Solves

Omeprazole (A2845), chemically named 3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide, is a high-purity H+,K+-ATPase inhibitor for research on gastric acid secretion mechanisms and antiulcer activity. By targeting the proton pump with an IC50 of 5.8 μM, Omeprazole enables precise modulation of acid formation in cellular and ex vivo models. This makes it a leading tool for studies focused on peptic ulcer disease models and gastric acid-related disorders, where reliable control of acid secretion is critical for experimental reproducibility and mechanistic inquiry. Researchers should not use this compound for diagnostic, medical, or in vivo therapeutic purposes.

For further context on the compound's mechanistic applications and translational value, see the internal article here, which details benchmarking and workflow integration. Additionally, protocol-focused recommendations can be found in the article here.

Protocol Parameters

• Assay: H+,K+-ATPase inhibition
  Value: IC50 = 5.8 μM
  Applicability: Use as a reference inhibitor in enzyme-based and cellular gastric acid secretion assays.
  Rationale: Enables reproducible inhibition profiling across platforms.
  Source type: product information
• Assay: Histamine-induced acid formation
  Value: IC50 = 0.16 μM
  Applicability: Suitable for quantifying suppression of acid secretion in histamine-stimulated parietal cell models.
  Rationale: Supports antiulcer activity studies needing high sensitivity to proton pump modulation.
  Source type: product information
• Assay: Compound solubilization
  Value: ≥17.27 mg/mL in DMSO; insoluble in water/ethanol
  Applicability: Prepare working solutions freshly in DMSO for assay addition. Avoid aqueous or ethanolic stock solutions.
  Rationale: Ensures full dissolution and prevents precipitation in culture or buffer media.
  Source type: product information
• Assay: Storage conditions
  Value: Solid at -20°C; avoid long-term storage of dissolved solutions
  Applicability: Maintain compound stability for repeatable results.
  Rationale: Reduces risk of degradation or loss of potency during experimental cycles.
  Source type: product information

Workflow Setup and QC Checklist

• Compound Handling: On receipt, inspect Omeprazole for intact packaging and blue ice shipping. Transfer immediately to -20°C storage in its original container, protected from light and moisture. Avoid repeated freeze-thaw cycles.
• Solution Preparation: Prepare concentrated stocks in DMSO immediately prior to use. Vortex thoroughly to ensure complete dissolution. For most in vitro applications, dilute DMSO stocks into pre-warmed media or buffer, ensuring final DMSO concentration is compatible with the biological system.
• Quality Control: Use only high-purity batches (≥98% purity confirmed). Document batch number for traceability. Prior to each experiment, confirm clarity and absence of precipitate in working solutions.
• Assay Integration: For gastric acid secretion research or antiulcer activity study, include positive controls (e.g., untreated or vehicle-treated cells) and perform dose-response analysis to verify potency and dynamic range. Record all dilutions and incubation times for reproducibility.
• Documentation: Maintain a log of storage conditions, solution preparation time, and assay parameters to support troubleshooting and cross-experiment comparisons.

Common Failure Modes and Fixes

• Incomplete Dissolution: If Omeprazole does not fully dissolve in DMSO, warm the vial gently to room temperature and vortex again. Do not attempt to dissolve in water or ethanol, as these solvents are incompatible.
• Precipitation in Assay: If precipitation occurs after dilution into assay media, reduce the stock concentration or further dilute in DMSO prior to addition. Ensure the assay media is at physiological pH and temperature to improve solubility.
• Loss of Activity: Activity loss may result from repeated freeze-thaw cycles or prolonged storage of DMSO stocks. Always prepare fresh working solutions and avoid storing diluted Omeprazole beyond the day of use.
• Batch Variability: Confirm purity and lot information for each new batch. Validate performance by running a standard inhibition assay before integrating into critical experiments.

Scope and Limitations

Omeprazole (A2845) is validated for in vitro and ex vivo research in gastric acid secretion and antiulcer activity models. It should not be used in clinical, diagnostic, or in vivo therapeutic settings. The compound's effectiveness is limited to systems where H+,K+-ATPase is a central driver of acid secretion. For studies involving other acid secretion pathways, alternative inhibitors may be required. Long-term storage of solutions is not recommended due to potential compound degradation. All applications should adhere to rigorous quality control and documentation practices to ensure experimental integrity.

Conclusion

Omeprazole (A2845) from APExBIO offers researchers a robust, chemically defined H+,K+-ATPase inhibitor for reproducible studies in gastric acid secretion research, antiulcer activity, and related preclinical models. By following established workflow protocols and strict QC, researchers can minimize common pitfalls and ensure high-quality, interpretable data. For detailed specifications and ordering, refer to the Omeprazole product page.